Guidance reaffirmed but Q1 delivery soft; H2 execution critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Guided 20% revenue growth YoY; Q1 delivered 6.7%. Reaffirmed guidance despite miss, citing external factors only.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order backlog (₹13.5K Cr) and bid pipeline (₹27K Cr) support multi-year growth, but Q1 revenue (+6.7%) and PAT (-15.2%) sharply miss the 20% guidance. Execution risk is high: major projects (IIT, NBCC, CIDCO) are behind schedule, margin is compressed by commodity inflation, and management's claim to catch up in H2 remains unproven. Hold until execution tangibly improves.
₹628.9 Cr
Revenue · +6.7% YoY₹39.8 Cr
Reported PAT · −15.2% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
20% revenue growth guidance well on track for full year
OVERSTATEDQ1 delivered only 6.7% YoY growth; needs ~28% avg H2 to hit 20% full year
Workmen shortages resolved, confident of full-year guided performance
PartialLabor normalized in June but Q1 already delivered; benefit unproven in Q2 yet
EBITDA margin 15.5–16.5% for FY27 is achievable
METQ1 at 15.7% within range but down from 17.2% YoY; compressed by ₹10 Cr provision
Strong order book of ₹13,535 Cr to drive revenue acceleration
MISSOrder book solid but execution constrained; IIT Bombay delayed, NBCC late to ramp, CIDCO only 2 of 7 locations active
Earnings quality
What changed since the last call
CapEx guidance raised
Upgrade₹165 Cr → ₹193 Cr (+₹28 Cr). Split: ₹121 Cr aluminum formwork, ₹56 Cr plant/machinery. Reflects new project needs and high-rise buildlings.
Revenue growth stalled
DowngradePrior 22% FY25, 12% FY26; Q1 FY27 is 6.7%. No formal guidance cut but implied path to 20% FY much harder post Q1 softness.
Commodity provision doubled
Downgrade₹10 Cr Q4 FY26 + ₹10 Cr Q1 FY27 = ₹20 Cr total hedges. Aluminum +35–40%, copper exposed; indices lag actual costs.
Order book size stable but execution timeline slipped
Neutral₹13.5K Cr OB unchanged but major projects (IIT, CIDCO, NBCC) all started later than prior-call plan. No order quantity cut, only timeline slip.
Debt reduction plan maintained
NeutralGross debt ₹522 Cr (up from Q4 due to payment timing, not structural increase). Net debt-free in 8 quarters reaffirmed despite CapEx uplift.
The Q&A
Analysts pressed hard on execution bottleneck: revenue growth slowed 22% → 12% → 6.7%, yet order book is 5x revenue. Management defended citing project-specific delays (tree permits, labor, client handover sequencing), reaffirmed 20% target, and argued bulk of revenue will come Q2–Q4. No admission of internal constraints; blamed only externals. Credibility questioned but not broken.
Revenue execution vs order book — Vinay Chaudhary, Invexa Capital
PartialIIT Bombay delayed by tree-cut permissions (should have ₹65–70 Cr Q1 revenue), NBCC only started ramping now (threefold increase coming), CIDCO only 2 of 7 locations handed over. Projects will ramp Q2–Q3. CAGR 2022–26 is ~20%, PAT CAGR >40%, so conversion track record is sound.
Commodity provisions reversal — Vinay Chaudhary, Invexa Capital
AnsweredAluminum up 35–40%, price variation not reflected yet in CPWD indices. Substantial portion expected to reverse Q3–Q4 as indices catch up. We've historically reversed large provisions over 7–8 years. Wait-and-watch approach; indices govern, not company opinion.
Revenue slowdown root cause — Vedant Kabra, Nuvama
PartialNot a bottleneck issue. CIDCO ₹2.5K Cr yet to start, NBCC rising from ₹15 Cr/month to ₹60 Cr/month, IIT Bombay just started. Order book includes sites not yet active. Our CAGR is 18% consol; 20% FY27 guidance means slight acceleration. Labor and technology improvements will support it from Q3–Q4.
Contract assets aging and quality — Gunit Singh, Cyclical PMS
PartialAll are milestone-based, cyclical, nothing >1–2 years overdue. CIDCO ₹300 Cr unbilled (work done, milestone pending), MHADA ₹200 Cr unbilled. Contract assets+debtors ratio is 78% (down from 120% post-COVID). Targeting leadership position by March 2028, matching pre-COVID levels.
Gross debt and capex impact — Vaibhav Shah, JM Financial
AnsweredGross debt up due to ₹150 Cr payment timing shift (already collected in current month), not structural. Equipment purchase may increase debt ₹45–50 Cr net. Working capital improving 25–30 days this year (like last year's 40 days reduction). Net debt trajectory on track.
Order backlog value and pricing — Vaibhav Shah, JM Financial
PartialNot '7 buildings' — total balance area is ₹2,000 Cr + escalation (28% price variation currently). In OB, we've booked ₹2,000 Cr. As locations handed over, we'll clarify building-by-building breakdown in Q2 call. Price variation can swing ±2–5%.
Provisioning and margin outlook — Deepak Poddar, Sapphire Capital
AnsweredNo provisioning expected Q2; will wait for Q3 indices before Q3 call commentary. EBITDA margins exclude other income. If prices stabilize and indices catch up, reversals in Q3–Q4.
Working capital and net debt-free timeline — Rahul Kumar, Vaikarya Fund
AnsweredNet working capital has improved 43 days last year. Expect 25–30 days improvement this year. Contract assets+receivables declining. Ideally revert to pre-COVID 56–72 days. March 2027 to March 2028 we should hit leadership position.
Guidance
FY27 revenue growth 20% YoY
MediumReaffirmed explicitly despite Q1 at +6.7%. Needs H2 to average ~28% growth. Executive team confident, citing Q2 Labor improved, IIT/NBCC/CIDCO/MHADA ramp Q2–Q4.
EBITDA margin FY27: 15.5–16.5%
MediumQ1 at 15.7% within range but lower half. Commodity provisions headwind; reversal hope Q3–Q4 if escalation indices catch up. Risk of further provisioning if indices lag.
CapEx FY27: ₹193 Cr (raised from ₹165 Cr)
HighSplit: ₹121 Cr formwork/aluminum extrusion, ₹56 Cr plant/machinery (high-rise & composite buildings), ₹5.4 Cr IT/SAP. Q1 done ₹52.2 Cr; on track.
Risks the call surfaced
Execution risk (projects delayed)
HighIIT Bombay (₹550 Cr) started Q2 instead of Q4 FY26 due to tree permits. NBCC late to profit ramp. CIDCO only 2 of 7 locations active. These delays cascade into H2 revenue miss.
Commodity inflation and margin pressure
HighAluminum +35–40%, copper exposed. Government contracts (55–60% of biz) have price variation clauses but indices lag actual purchase costs. ₹10 Cr provision Q4 + ₹10 Cr Q1 = ₹20 Cr total hedges. If indices don't catch up, further provisions or margin cuts needed.
Revenue growth credibility
HighQ1 delivered 6.7% growth YoY; guidance is 20% for full year. To hit 20%, H2 must average ~28% growth. No single quarter since FY25 has delivered >12% growth. Feasibility highly dependent on timing of CIDCO, MHADA, NBCC ramps.
Contract asset aging and realization risk
MediumContract assets + debtors at 78% of revenue (down from 120% post-COVID). Nothing is >1–2 years overdue (all milestone-based), but high absolute amount suggests working capital intensity. Any client payment delays cascade into cash burn.
External constraints (permits, labor, environment)
MediumQ1 hit by Mumbai water cuts, labor shortages (30% in June), tree permits (IIT). Delhi NCR GRAP (Nov–Jan) could cost ~20 days or more if AQI >400. Management factored these in but external risk remains high.
Management
Score 6/10. Detailed on project-level breakdowns (CIDCO, MHADA, NBCC, IIT, Signature Global); transparent on order pipeline (₹27K Cr identified bids). However, defensive on guidance miss (blames only externals, no internal accountability). Some questions (contract asset aging) deflected to offline conversation. Track record mixed: FY26 guided 20%, delivered 12%. CAGR 2022–26 solid at ~18–20% consol, but recent slowdown (22% FY25 → 12% FY26 → 6.7% Q1 FY27) is concerning. PAT CAGR >40% prior years now down -15.2% YoY, showing profitability weakness.
1 · Q2 FY27 (Sept 2026)
IIT Bombay execution ramp, NBCC monthly run rate to ₹60 Cr, CIDCO land handover begins
2 · Q3 FY27 (Dec 2026)
Major revenue inflection from 4+ new project locations; CIDCO ₹75+ Cr, MHADA ₹75 Cr, others
3 · Delhi NCR GRAP (Nov–Jan)
Construction ban for ~20 days; management factored this, but risk if AQI > 400
Hold until execution tangibly improves.
Informational and educational content only. Not investment advice.